Navigation Links
Lymphocytic in Medical News

New Report Just Published: World Multiple Myeloma Therapeutics Market Report

... Lymphoma), Multiple Myeloma, Leukemia (Acute lymphocytic Leukemia, Chronic lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic ... Cancers II-30 Leukemia II-30 Acute lymphocytic Leukemia II-30 ...

Damon Runyon Cancer Research Foundation awards $2.7M to 7 top young clinical investigators

... modified immune T cells to treat chronic lymphocytic leukemia (CLL). His Continuation Grant will be ... trial to treat pediatric patients with acute lymphocytic leukemia (ALL). These are patients for whom all ... of two types of pediatric leukemias, acute lymphocytic leukemia (ALL) and acute myelogenous leukemia ...

Gene Studies Reveal Cancer's Secrets

... genetic variants increases the risk for chronic lymphocytic leukemia (CLL). The findings of this study add ... "if you have a family member with chronic lymphocytic leukemia, your chances of getting the disease are ... polymorphisms" (SNPs) that might lead to chronic lymphocytic leukemia. In the current study, researchers ...

GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer

... (ofatumumab) to treat patients whose chronic lymphocytic leukemia (CLL) is resistant (refractory) to ... Ofatumumab is being developed to treat chronic lymphocytic leukemia, non-Hodgkin's lymphoma, diffuse large ... January 28, 2009. (2) Eichhorst B. Chronic lymphocytic leukemia: ESMO Clinical Recommendations for ...

GlaxoSmithKline's Drug Will Become New Clinical Gold Standard by 2012 for the Treatment of Relapsed/Refractory CLL

... treatment for relapsed/refractory chronic lymphocytic leukemia (CLL) by 2012. This shift is due to ... new report entitled Relapsed/Refractory Chronic lymphocytic Leukemia: Physicians Are Eager for Increasingly ... About the Report Relapsed/Refractory Chronic lymphocytic Leukemia: Physicians Are Eager for Increasingly ...

Late-breaking data to be presented at the American Society of Hematology Annual Meeting

... in patients with relapsed or refractory chronic lymphocytic leukemia, the first large-scale study examining ... the way we treat patients with advanced chronic lymphocytic leukemia," said Linda Burns, MD, moderator of the ... Survival in Relapsed or Refractory Chronic lymphocytic Leukemia (CLL) Compared with FC Alone: Final ...

Novel treatments show improvements in survival and response rates for leukemia and lymphoma

... therapy for the treatment of advanced chronic lymphocytic leukemia, the examination of pralatrexate for the ... a slower rate. Leukemias also are categorized as lymphocytic or myelogenous depending on whether they affect ... in Diffuse Large B-Cell Lymphoma and Chronic lymphocytic Leukemia [Abstract #3] Jonathan W. Friedberg, ...

Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma

... therapy for the treatment of advanced chronic lymphocytic leukemia, the examination of pralatrexate for the ... a slower rate. Leukemias also are categorized as lymphocytic or myelogenous depending on whether they affect ... Diffuse Large B-Cell Lymphoma and Chronic lymphocytic Leukemia [Abstract #3] Jonathan W. ...

Researchers Tackle CLL, Diabetes and Trauma-Hemorrhage

... in the November/December issue: “Chronic lymphocytic Leukemia Cells Recognize Conserved Epitopes ... (Vocus) November 14, 2008 -- Chronic lymphocytic Leukemia (CLL) is a disease of the B lymphocytes ... from this type of normal B lymphocyte. Chronic lymphocytic Leukemia Cells Recognize Conserved Epitopes ...

WellPoint's Health Plans to Cover Newly Approved Cancer Treatment

... its availability to members with chronic lymphocytic leukemia INDIANAPOLIS, March 24 ... to grant it orphan drug status for chronic lymphocytic leukemia. According to the National Cancer Institute, chronic lymphocytic leukemia is the second most common type ...

Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkin's Lymphoma Patients

... mantle cell lymphoma (MCL), and chronic lymphocytic leukemia (CLL) patients. At the time of the ... indolent B-cell lymphoma, excluding chronic lymphocytic leukemia and NHL with central nervous system ... of Medicinal Products for MCL and chronic lymphocytic leukemia. MT103 specifically targets the ...

FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia

... for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). Campath was initially approved ... States as MabCampath(R). About B-Cell Chronic lymphocytic Leukemia According to the Leukemia and Lymphoma ... approximately 15,000 new cases of B-cell chronic lymphocytic leukemia (B-CLL) are diagnosed in the U.S. each ...

2 NYU scientists named Howard Hughes Medical Institute's Early Career Scientists

... programs. Dr. Aifantis, a cancer biologist investigating T-cell acute lymphocytic leukemia, a common form of leukemia in children and Dr. Dasen, a ... towards understanding and developing new treatments for T-cell acute lymphocytic leukemia. He recently discovered a molecular door by which T cells, the ...

Two NYU Scientists Named Howard Hughes Medical Institute's early career scientists

... programs. Dr. Aifantis, a cancer biologist investigating T-cell acute lymphocytic leukemia, a common form of leukemia in children and Dr. Dasen, a ... towards understanding and developing new treatments for T-cell acute lymphocytic leukemia. He recently discovered a molecular door by which T cells, the ...

Medarex Highlights Oncology Pipeline at Needham Cancer Therapeutics Conference in New York City

... is a fully human anti-CD19 antibody in Phase 1 development for chronic lymphocytic leukemia (CLL). Proof-of-concept pharmacologic Phase 1 data for CLL, as ... arthritis, is expected in 2009. Initiation of the Phase 1 trial in acute lymphocytic leukemia remains on track for fourth-quarter 2009. MDX-1401 is a ...

Signs of Leukemia Show Up Years Before Diagnosis

... Study suggests abnormal blood cells hold clues to start of chronic lymphocytic leukemia WEDNESDAY, Feb. 11 (HealthDay News) -- Abnormal ... can appear in the blood years before a person is diagnosed with chronic lymphocytic leukemia (CCL), U.S. researchers say. They added that this finding may ...

Dismissed leukemia drug helps cll patients, studies show

... Ohio A drug once dismissed as ineffective in patients with chronic lymphocytic leukemia (CLL) has shown promising results in two phase I and II clinical ... five ASCO abstracts to be featured during the Joint Symposium. Chronic lymphocytic leukemia is the most common type of adult leukemia, with some 15,000 new ...

Canadian cold/flu breakthrough remedy undergoes NCI-sponsored trial in leukemia patients

... product in Canada ginseng extract COLD-FX reduces infections in chronic lymphocytic leukemia patients; enabling them to remain healthier to fight their ... increase risk of infection, the most common complication" of chronic lymphocytic leukemia. "Two randomized, controlled trials have shown that an extract ...

Fudan-Cinpathogen Study Shows Chronic Lymphoid Neoplasms are More Common in Shanghai Than Thought

... between China and the West. The report also reveals that chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), previously thought to be rare in China, is more common ...

JCI online early table of contents: June 12, 2008

... not been clearly determined. New insight into the way in which chronic lymphocytic leukemia (CLL) cells limit immune cell attack has now been provided by ... the antitumor activity of CD4+ and CD8+ T cells. TITLE: Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be ...

The Monoclonal Antibodies Drug Market for the Treatment of Cancer Will More Than Double to $16.7 Billion By 2016

... of the disease, this agent is forecasted to gain approval for chronic lymphocytic leukemia, allowing for increased prescribing in Europe where the ... Genmab/GlaxoSmithKline's ofatumumab for non-Hodgkin's lymphoma and chronic lymphocytic leukemia, Medarex/Bristol-Myers Squibb's ipilimumab for malignant myeloma, ...

Microenvironment a main driver of aggressive multi-lineage leukemia disease type

... are acute myeloid leukemia (AML), acute lymphoid leukemia (ALL), chronic lymphocytic leukemia (CLL) and chronic myelogenous leukemia (CML). Mixed lineage ... AML, their usefulness is considered limited for modeling the lymphocytic and mixed myeloid/lymphoid forms of the disease. The research team ...

New drug combination brings 1-2 punch against acute leukemia

... induced more than 90 percent cell death in human tissue cultures of acute lymphocytic leukemia. She presented her study at the American Society of Pediatric ... showed that the two together have a more powerful impact on treating acute lymphocytic leukemia, which is the most common childhood cancer." Glycolysis is a ...

Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology

... non-clinical data showing that SNS-032 induces apoptosis in chronic lymphocytic leukemia (CLL) cells are being presented by William Plunkett, Ph.D., ... Action of SNS-032, a Novel Cyclin-Dependent Kinase Inhibitor, in Chronic lymphocytic Leukemia: Comparison with Flavopiridol (Abstract # 3112) Results from a ...

Advances in Blood Cancer Therapy to be Highlighted at American Society of Hematology Conference

... Status as Major Determinant of Response to MDM2 Inhibitors in Chronic lymphocytic Leukemia, Shaomeng Wang, Ph.D., University of Michigan, (Dec. 10, 7:45 ... will host this year's Marshall A. Lichtman Research Symposium, Chronic lymphocytic Leukemia as a Model of Translational Research, on Friday, Dec. 7, 7 a.m., ...

New class of RNA molecules may be important in human cancer

... and his colleagues measured the activity of UCR genes in human chronic lymphocytic leukemia, and colorectal and liver cancer. Overall, they examined 133 ... of five UCRs able to differentiate a slowly progressing form of chronic lymphocytic leukemia and a form that progresses quickly and aggressively. At the ...

Sagent Pharmaceuticals Announces Launch of First Two Oncolytic Products: Fludarabine Phosphate for Injection, USP and Epirubicin Hydrochloride Injection

... equivalent to Fludara(R), distributed by Bayer HealthCare Pharmaceuticals) is indicated for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing ...

Silenced genes as a warning sign of blood cancer

... is when the first labels occur in the development of cancer. In their recently published study the investigators used mice affected by chronic lymphocytic leukemia as a model for studying the disease. The researchers investigated the genetic material of these mice at regular intervals from birth. ...

Journal of Clinical Oncology Publishes TREANDA Study Demonstrating Significant Improvement in Overall Response and Progression-Free Survival in Chronic Lymphocytic Leukemia

... demonstrating that TREANDA(R) (bendamustine HCl) for Injection improved clinical outcomes when compared to chlorambucil in patients with chronic lymphocytic leukemia (CLL). Results of this study were the basis of the March 2008 U.S. Food and Drug Administration (FDA) approval of TREANDA for CLL, the ...

BioCryst Reports Second Quarter 2009 Financial Results And Provides Corporate Update

... than 12 months. A Phase 2 single-arm, open-label study evaluating 200 mg of forodesine twice-daily in patients with chronic lymphocytic leukemia is ongoing, and the Company expects to provide an update on this study by the end of 2009. Conference Call and Web Cast ...

Agent Orange Linked to Parkinson's, Heart Disease

... follow: It found "sufficient" evidence of a link between herbicide exposure and soft-tissue sarcoma, non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL) and other chronic B-cell leukemias, Hodgkin's disease and chloracne, a skin condition. The committee also clarified that hairy cell ...

Limited data suggest possible association between Agent Orange exposure

... for clarification by the U.S. Department of Veterans Affairs, the committee also affirmed that hairy cell leukemia is in the same category as chronic lymphocytic leukemia (CLL) and lymphomas. Previous reviews in the series found sufficient evidence to state that there is an association between herbicide ...

Public Health Experts Discuss Infectious Diseases Threats at News Conference

... which have been associated with outbreaks include Salmonella species, E. coli 0157:H7, Campylobacter species, Cryptosporidum species, and lymphocytic choriomeningitis. Dr. Pickering discussed regulations and recommendations applicable to these exposures and defined measures which can minimize or ...

Prospect Therapeutics Inc.'s GCS-100 Has Focused on Developing Treatment for Three Blood-Borne Cancers

... C.P.A. ("Finn") announced today that Prospect Therapeutics has focused on developing GCS-100 for treatment of three blood-borne cancers: chronic lymphocytic leukemia ("CLL"), multiple myeloma ("MM") and diffuse large B cell lymphoma ("DLBCL"). In clinical studies, GCS-100 has demonstrated activity as a ...

Transplant drug stimulates immune memory

... produces an abundance of T cells to fight an infection or respond to a vaccine. Araki had been examining rapamycin's effects in mice infected with lymphocytic choriomeningitis virus (LCMV). "Usually during the response to this virus, 90 percent of the CD8 T cells produced to fight an infection die after ...

The Leukemia & Lymphoma Society Calls for Blood Cancer Research Program at the Department of Defense

... program at the Department of Defense (DoD). The Institute of Medicine (IOM) has determined that several blood cancers, including chronic lymphocytic leukemia (CLL), lymphoma and multiple myeloma, are associated with exposure to chemical and biological agents from the Vietnam and two Gulf Wars. ...

New arenavirus discovered as cause of hemorrhagic fever outbreak in South Africa and Zambia

... using genetic extracts of blood and liver from the victims and through unbiased high-throughput sequencing, is distantly related to Lassa virus and lymphocytic choriomeningitis virus (LCMV). Characterization of the novel virus confirms the utility of unbiased high-throughput sequencing for pathogen ...

Immune exhaustion driven by antigen in chronic viral infection

... in a molecular frame supplied by other cells in the body -- called MHC (major histocompatibility complex) class I molecules. In mice infected by lymphocytic choriomeningitis virus (LCMV), T cells became more or less exhausted depending on how much properly framed viral protein was available. Insights ...

Research Findings on Nine GlaxoSmithKline Cancer Compounds to be Presented at ASCO 2009

... mAB, is active regardless of prior rituximab exposure in patients with fludarabine-and alemtuzumab-refractory or bulky fludarabine-refractory chronic lymphocytic leukemia (CLL)." Dr. W. Wierda, MD Anderson, the University of Texas MD Anderson Cancer Center; Poster presentation on May 30. ...

Researchers find drug that inhibits acute leukemia cell growth

... cure rate of 80 percent, but children with the rarer type, AML, have only a 50 percent chance of a cure in comparison. "Young patients with acute lymphocytic leukemia have a great chance of being cured using the standard treatments available out there today," said Patrick Zweidler-McKay, M.D., Ph.D., ...
Other Contents
(Date:2/13/2015)... ACT Genomics Co., Ltd., a cancer ... cancer genomic information into precision diagnosis and personalized ... US$ 8 million in the its first private funding ... Taiwan , ACT Genomics has developed comprehensive ... to implement next generation sequencing (NGS) and multiplex ...
(Date:2/12/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announced ... DISTRIBUTED METHOD AND SYSTEM TO IMPROVE COLLABORATIVE ... establishes NXT-ID,s position in the emerging "Internet of Things" ... for multiple devices to collaborate with one another to ...
(Date:2/10/2015)... Inc. (NYSE: ALR), a global leader in rapid ... ended December 31, 2014. Namal Nawana, ... "We made substantial progress in the fourth quarter ... rapid diagnostics and delivering against our financial plans.  ... January enabled us to substantially reduce our debt, ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33
(Date:3/6/2015)... Jose, California (PRWEB) March 06, 2015 ... also known as the pharmacokinetics of a drug refers ... a pharmaceutical compound inside an organism. When toxicity studies ... ADME-Tox or ADMET or ADME/Tox. Increasing focus on lowering ... adoption of ADME-toxicology testing worldwide. The traditional drug development ...
(Date:3/6/2015)... NY (PRWEB) March 06, 2015 Ticket Down ... . This popular ticket exchange has extended their customer appreciation ... from Hebden Bridge, West Yorkshire England and he began his ... In the past couple of years Ed Sheeran has ... whenever Ed Sheeran is on stage he is having the ...
(Date:3/6/2015)... CA (PRWEB) March 06, 2015 US ... of three Maryland camps – two non-contact specialty camps ... be run by Perfect Performance Training, located at Bowie ... focus on developing position specific skills, speed and strength ... hosted at Salisbury University with Marvin Graves, former quarterback ...
(Date:3/6/2015)... As the Association of American Medical Colleges' ... by 2025 is updated this week and debated in ... preparing by analyzing demographics and pursuing viable solutions for ... factors including the increasing number of retiring doctors, increasing ... Care Act and an uneven distribution of new doctors ...
(Date:3/6/2015)... 2015 First Choice Emergency Room ... facility is located at 13351 W. Bowles Avenue, Littleton, Colorado ... is ready 24-7 to provide the highest quality emergency medical ... Director of First Choice Emergency Room Littleton. , ... South Metro Denver Chamber of Commerce and a medical community ...
Breaking Medicine News(10 mins):Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Ed Sheeran Tickets in Indianapolis, Austin, Albany, St. Louis, London, Des Moines, Salt Lake City, Saskatoon, Regina and Denver/Morrison Now On Sale at Ticket Down 2Health News:US Sports Camps to Host Three New Football Camps in Maryland 2Health News:Susquehanna Health Plans Progressively to Prevent Projected Physician Shortfall 2Health News:Susquehanna Health Plans Progressively to Prevent Projected Physician Shortfall 3Health News:Susquehanna Health Plans Progressively to Prevent Projected Physician Shortfall 4Health News:First Choice Emergency Room Opens New Facility in Littleton, Colorado 2
Other TagsOther Tags